Brief: Adc Therapeutics SA Says Expected Cash Runway Extended Into Middle Of 2025
28/02/2023 14:53
Feb 28 (Reuters) - ADC Therapeutics SA ADCT.N :
* EXPECTED CASH RUNWAY EXTENDED INTO MIDDLE OF 2025
* ANTICIPATED DECREASE IN TOTAL OPERATING EXPENSES IN 2023
AND
2024 AS COMPARED TO 2022
* EXPECTED TO GROW ZYNLONTA FY 2023 NET PRODUCT SALES BY A
DOUBLE-DIGIT PERCENTAGE YEAR-OVER-YEAR
* QTRLY LOSS PER SHARE $0.30
Source text for Eikon: ID:nBwc7vQ2ga
Further company coverage: ADCT.N
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview